The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 5000 participants.

Also called NCT03129555

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03129555
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03129555. Randomized; single masking; primary purpose treatment. Start 2023-04-01 (actual); primary completion 2027-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
Acronym
DANNOAC-VTE
Intervention (Drug)
Dabigatran Etexilate Oral Capsule
Intervention (Drug)
Rivaroxaban Oral Tablet
Intervention (Drug)
Edoxaban Oral Tablet
Intervention (Drug)
Apixaban Oral Tablet
Lead sponsor
Herlev and Gentofte Hospital (class: other)

Record details

Record id
cardio:ct-nct03129555
Content hash
df076105016fe6cb2fd07265c9d71d62c92d32332b9c7a507bbe1a0b4b5c3bf9